Latest studies
- RecruitingPhase IV
The 3TR-PARTNER-RA study: Are RNA signatures (biomarkers) in the tissue which surrounds the joints (synovial tissue) from patients with early Rheumatoid Arthritis (symptoms <12 months) predictive of response to biologic drug treatments?
This UK clinical study investigates whether testing a tiny sample of joint tissue can help doctors choose the most effective treatment for early rheumatoid arthritis. Researchers want to see if specific biological markers can predict whether a modern medicine called abatacept works well for newly diagnosed patients.
Rheumatoid arthritisPortugal - CompletedPhase II
Testing new medicine for adults with Cystic Fibrosis who do not have access to the currently available CFTR-modulating drugs due to genetic mutations
This clinical trial tests a new three-in-one medicine for adults with cystic fibrosis who have rare genetic mutations. These patients cannot access currently approved treatments. Researchers are checking whether this daily combination of capsules can safely improve lung health after promising results in laboratory tests using patient cell samples.
Treatment of Cystic Fibrosis (CF) in patients with CFTR mutations who are responders in the organoid assayPortugal - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
Metastatic Pancreatic Ductal AdenocarcinomaPDACPortugal - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorPortugal - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.Portugal - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseasePortugal - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fed Conditions.
This study tests a 50 mg mirabegron tablet in healthy adults. Mirabegron is usually used to treat overactive bladder. Researchers want to check if a new tablet releases medicine into the body in the same way as the standard version when taken after eating a meal.
No medical condition.Portugal - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.
This clinical trial is testing a new version of a tablet called mirabegron. Researchers want to check if this tablet releases medicine into the bloodstream in the same way as the approved brand. The study is for healthy adult volunteers aged 18 and older who do not have major medical conditions.
No medical condition.Portugal - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.
This clinical study tests a new, smaller 'mini-tablet' version of indapamide, a common medicine used to lower high blood pressure. Researchers want to see if the body absorbs this mini-tablet in the exact same way as standard, larger tablets when taken by healthy adult volunteers on an empty stomach.
No medical condition.Portugal - RecruitingTherapeutic confirmatory (Phase III)
KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
This clinical trial compares a new targeted drug called JDQ443 with standard chemotherapy (docetaxel). It is for adults with advanced non-small cell lung cancer that carries a specific genetic change called KRAS G12C. Researchers want to find out which treatment keeps cancer from growing for longer.
Advanced non-small cell lung cancer harboring the KRAS G12C mutationPortugal - Completed
A multi-site observational study looking at the risk factors associated with tooth sensitivity, receding gums and tooth wear
This study looks into why adults develop sensitive teeth, receding gums, and worn tooth enamel. Researchers are studying how diet, brushing, and lifestyle affect oral health across Europe. Taking part is simple: it involves completing a short lifestyle survey and having a gentle mouth check-up during a single dental appointment.
Dentine hypersensitivity Tooth wear Recession Clinical loss of attachment Oral hygiene habits Dietary habitsPortugal - AuthorisedPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome
This early clinical trial is testing an experimental medicine called ION337 for people with Dravet syndrome. Researchers want to find out if the drug is safe, how the body handles it, and whether it can help reduce the number of major seizures patients experience.
Dravet SyndromePortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
This study tests an inhaled dry powder medicine called treprostinil palmitil for adults with high blood pressure in the lungs linked to lung scarring. The trial lasts up to two years to see if the medicine is safe and helps improve breathing, walking ability, and overall quality of life.
Pulmonary Hypertension Associated with Interstitial Lung DiseasePortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Portugal - RecruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3
This study tests a new experimental drug, S233107, for adults living with spinocerebellar ataxia type 3 (SCA3). Because this is the first time the medicine is tested in people, researchers want to see if it is safe, how well the body handles it, and how it moves through spinal fluid.
Spinocerebellar ataxia type 3Portugal - AuthorisedTherapeutic exploratory (Phase II)
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
This study looks at a new drug combination for older or frail adults with diffuse large B-cell lymphoma, a type of blood cancer. Researchers want to see if adding an antibody drug called epcoritamab to standard, gentler chemotherapy helps clear the cancer better and keeps people well for longer.
Diffuse large B-cell lymphoma (DLBCL)Portugal - AuthorisedTherapeutic exploratory (Phase II)
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
This clinical trial is testing a new nasal spray called cenegermin for adults with NAION, an eye condition causing sudden sight loss. Researchers want to see if this treatment helps repair damaged nerve cells and improves vision on an eye chart over a period of 24 weeks.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)Portugal - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Portugal - AuthorisedTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age with Systemic Lupus Erythematosus.
This study looks at a medicine called anifrolumab (Saphnelo) in children and young people aged 5 to 17 with lupus. Researchers want to find out how the body handles the medicine given as an injection under the skin, and to check that it is safe for younger patients.
Systemic Lupus ErythematosusPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
This Phase 3 clinical trial tests a new drug called mocertatug rezetecan for womb (endometrial) cancer. Researchers want to see if it works better and is safer than standard chemotherapy for people whose cancer has returned or worsened after earlier treatments like platinum chemotherapy and immunotherapy.
Neoplasms, EndometrialPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
This clinical trial is testing a new injection called lebrikizumab for people with moderate-to-severe eczema on their face and neck. Researchers want to see if the medicine can clear skin, soothe itching, and improve daily life over 16 weeks compared to a dummy injection (placebo).
Face and Neck Atopic DermatitisPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
This study tests a new medicine called claseprubart (DNTH103) for generalised myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if the medicine safely improves muscle strength and helps with daily activities compared to a dummy drug (placebo) in adults aged 18 and older.
generalized Myasthenia gravisPortugal - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
This early-stage clinical trial tests a new targeted radiation treatment for people with advanced solid tumours, such as lung, breast, bladder, or stomach cancer. The trial aims to find safe doses and see how well a special scanning dye and a radiotherapy drug work together to find and treat cancer.
Advanced bladder cancer, Advanced Breast cancer (HER2+, HR+/HER2-negative or TNBC), Advanced Non-small cell lung cancer (NSCLC), Advanced gastric/Gastroesophageal junction adenocarcinoma (GEJ) cancerPortugal - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1
This clinical trial looks at a new long-acting injection for adults with HIV-1 who have not started treatment before. It compares an injectable combination of two medicines, GS-3242 and lenacapavir, against a standard daily tablet called Biktarvy. The goal is to see if injections work just as well as daily pills.
human immunodeficiency virus type 1 (HIV-1)Portugal - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).
This clinical trial is testing a potential new medicine called pridopidine for adults with Huntington’s disease. Researchers want to see if taking this medicine daily for one year can safely help slow down changes in movement, thinking, and everyday tasks compared to an inactive dummy pill (a placebo).
Huntington’s disease (HD).Portugal - AuthorisedTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, multicenter Phase 2a/b study assessing the efficacy, safety and tolerability of DDY391 in participants with Sjögren's Disease
This clinical trial is testing a new medicine called DDY391 for adults with Sjögren's disease. Researchers want to see if it safely relieves common symptoms like dry eyes, dry mouth, joint pain, and exhaustion. Participants are randomly chosen to receive either DDY391 or a dummy treatment (placebo).
Sjögren's DiseasePortugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisPortugal - RecruitingPhase I and Phase II (Integrated)- First administration to humans
Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors
This clinical trial is testing a new drug called elraglusib in adults with blood cancers or solid tumours. It looks at whether elraglusib, taken alone or alongside standard chemotherapy medicines, is safe and can help control cancer that has not responded to other treatments.
Refractory Hematologic Malignancies or Solid TumorsPortugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study is testing a new injection called ION-682884 for adults with a serious heart condition called ATTR-CM. Researchers want to find out if this medicine can protect the heart, lower the need for hospital care, and help people live longer compared to a dummy treatment (placebo).
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Portugal - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, randomized, open-label trial of GEN1046 as monotherapy and in combination with Pembrolizumab in subjects with relapsed/refractory metastatic non-small cell lung cancer after treatment with standard care therapy with a immune checkpoint inhibitor.
This study is testing a new drug called acasunlimab for people with advanced non-small cell lung cancer. It looks at whether taking acasunlimab on its own, or alongside an immunotherapy drug called pembrolizumab (Keytruda), can help shrink tumours after previous treatments have stopped working.
Malignant Solid Tumors - Non Small Cell Lung CancerPortugal - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Portugal - RecruitingTherapeutic confirmatory (Phase III)
An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension
This clinical trial is testing a medicine called leniolisib for young children aged 1 to 6 with a rare immune condition called APDS. Children with APDS often have frequent infections and swollen glands. Doctors want to see if the medicine is safe, easy to take, and improves their health.
Activated Phosphoinositide 3-Kinase Delta SyndromePortugal - RecruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo controlled, Proof of Concept (PoC) study to assess the efficacy, safety and tolerability of itepekimab in participants with inadequately controlled chronic rhinosinusitis without nasal polyps
This clinical trial is testing a new medicine called itepekimab for adults with ongoing sinus swelling that has not cleared up with standard treatments. Researchers want to find out if the medicine can safely reduce inflammation inside the sinuses, clear blockages seen on CT scans, and relieve everyday nasal symptoms.
Respiratory tract diseasesPortugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseasePortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
This clinical study tests two new medicines, REGN7508 and REGN9933, for adults with atrial fibrillation (an irregular heartbeat). It aims to find out if these treatments can safely stop blood clots and strokes in people who cannot take standard blood-thinning tablets due to a high risk of bleeding.
Atrial Fibrillation (AF)Portugal - RecruitingTherapeutic exploratory (Phase II)
An adaptive, randomized, double-blind, dose exploration, parallel group, placebo controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V
This study looks at a new drug called iptacopan (LNP023) for adults with lupus nephritis, a kidney problem caused by lupus. Researchers want to see if adding it to usual care helps heal the kidneys, cuts down lupus flare-ups, and lowers the need for strong steroid medications.
Lupus Nephritis Class III-IV, +/- VPortugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for cancer of the gullet (oesophagus) that cannot be removed by surgery. Researchers want to see if using immunotherapy drugs, called atezolizumab and tiragolumab, after standard chemotherapy and radiotherapy can help stop the cancer from returning and help people live longer.
Unresectable Esophageal Squamous Cell CarcinomaPortugal - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy (PROTECT)
This phase 3 clinical study tests a new medicine called sparsentan for adults with IgA nephropathy, a serious kidney condition. Researchers want to see if sparsentan is better at reducing protein leaks in urine and protecting kidney function over time compared to a standard medicine called irbesartan.
Immunoglobulin A Nephropathy (IgAN)Portugal - RecruitingTherapeutic confirmatory (Phase III)
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
This study looks at a medicine called sotatercept for adults with pulmonary arterial hypertension (PAH). Researchers want to see how safe it is over a longer period when taken alongside usual treatments. It also checks whether the medicine helps improve walking ability, heart health, and everyday energy levels.
Pulmonary Arterial Hypertension (PAH)Portugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults
This study tests whether a medicine called dupilumab can help adults with lichen simplex chronicus, also known as neurodermatitis. Researchers want to see if the treatment relieves severe itching, improves sleep, and clears thickened patches of skin compared to a dummy injection (placebo) over 24 weeks.
NeurodermatitisPortugal - RecruitingTherapeutic exploratory (Phase II)
KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
This phase 2 clinical trial looks at a new targeted medicine called JDQ443. It is for adults with advanced non-small cell lung cancer that has specific gene changes, including KRAS G12C. The study tests how well this medicine shrinks tumours when used as a first treatment.
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.Portugal - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
This study looks at a medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). ITP causes low blood platelets, leading to easy bruising and bleeding. Researchers want to see if an injection under the skin is safe and helps keep platelet counts at a healthy level over time.
Primary Immune ThrombocytopeniaPortugal - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
This phase 3 clinical trial is looking at a new combination of immunotherapy drugs given alongside chemotherapy. It aims to find out if this new combination helps people with untreated, advanced cancer of the stomach or food pipe live longer compared to the current standard immunotherapy and chemotherapy treatment.
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric CancerPortugal - AuthorisedPhase II and Phase III (Integrated)
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
This clinical trial is testing a new targeted medicine called telisotuzumab adizutecan, combined with chemotherapy, for people with advanced pancreatic cancer. Doctors want to see if this new combination shrinks tumours better and helps people live longer compared with standard chemotherapy treatments currently used on the NHS.
Metastatic Pancreatic Ductal AdenocarcinomaPDACPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).
This study looks at adults with type 2 diabetes who take metformin but still have high blood sugar. Researchers want to see if taking two diabetes medicines together (alogliptin and empagliflozin) lowers blood sugar levels better and more safely than taking either medicine on its own.
Type 2 Diabetes mellitusPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
This study tests a new medicine called LYT-100 for idiopathic pulmonary fibrosis (IPF). Researchers want to see if it works as well as or better than pirfenidone, an existing treatment, to protect lung capacity over one year. It is open to adults aged 18 and older with IPF.
Idiopathic Pulmonary FibrosisPortugal - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
This study is testing a new combined vaccine that aims to protect against both flu and COVID-19 in a single jab. Researchers want to see if this combination produces strong immune defences and is safe compared to giving standard, separate flu and COVID-19 vaccines.
COVID-19, InfluenzaPortugal - RecruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.
This study is testing a new, smaller 'mini-tablet' version of indapamide, a medicine used for high blood pressure. Healthy adults will help researchers see how the body absorbs this new tablet compared to the standard version, and whether taking it with food changes how it works.
No medical condition.Portugal - AuthorisedTherapeutic confirmatory (Phase III)
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
This study looks at the long-term safety of a medicine called admilparant for people with pulmonary fibrosis. Researchers want to see how well the body handles the treatment over time, tracking any side effects and checking heart health and blood tests to make sure it is safe to use.
Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosisPortugal - AuthorisedPhase II and Phase III (Integrated)
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
This clinical trial is testing a medicine called pegcetacoplan for people with focal segmental glomerulosclerosis (FSGS), a rare kidney condition. Researchers want to see if the treatment safely reduces the amount of protein leaking into the urine and helps protect kidney function over time.
Focal segmental glomerulosclerosis (FSGS)Portugal